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Background: Muscle wasting and chronic inflammation are predominant features of patients 
with COPD. Systemic inflammation is associated with an accelerated decline in lung function. 
In this study, the prevalence of sarcopenia and the relationships between sarcopenia and systemic 
inflammations in patients with stable COPD were investigated.
Materials and methods: In a cross-sectional design, muscle strength and muscle mass were 
measured by handgrip strength (HGS) and bioelectrical impedance analysis in 80 patients with 
stable COPD. Patients ($40 years old) diagnosed with COPD were recruited from outpatient 
clinics, and then COPD stages were classified. Sarcopenia was defined as the presence of both 
low muscle strength (by HGS) and low muscle mass (skeletal muscle mass index [SMMI]). 
Levels of circulating inflammatory biomarkers (IL-6 and high-sensitivity TNFα [hsTNFα]) 
were measured.
Results: Sarcopenia was prevalent in 20 (25%) patients. Patients with sarcopenia were older, 
had lower body mass index, and a higher percentage of cardiovascular diseases. In addition, they 
had significantly higher modified Medical Research Council scores and lower 6-minute walk 
distance than those without sarcopenia. HGS was significantly correlated with age, modified 
Medical Research Council score, and COPD Assessment Test scores. Both HGS and SMMI 
had associations with IL-6 and hsTNFα (HGS, r=-0.35, P=0.002; SMMI, r=-0.246, P=0.044) 
level. In multivariate analysis, old age, lower body mass index, presence of cardiovascular 
comorbidities, and higher hsTNFα levels were significant determinants for sarcopenia in 
patients with stable COPD.
Conclusion: Sarcopenia is very common in patients with stable COPD, and is associated with 
more severe dyspnea-scale scores and lower exercise tolerance. Systemic inflammation could 
be an important contributor to sarcopenia in the stable COPD population.
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Introduction
COPD is a leading cause of morbidity and mortality worldwide. It is characterized 
by persistent, progressive limitations in airflow, which are usually associated with 
enhanced airway and lung-inflammatory responses to noxious particles or gases.1 
Systemic inflammation is associated with an accelerated decline in lung function, 
and is heightened during episodes of exacerbation.2,3 Systemic inflammation is now 
a recognized risk factor for other complications commonly observed in patients with 
COPD, including atherosclerosis,4 cachexia,5 anorexia,6 and osteoporosis.7 It is present 
not only in acutely exacerbated COPD but also in stable COPD.8
Muscle wasting is another characteristic feature of COPD,9 and evaluation of both 
muscle quality and quantity are essential. Physical inactivity is involved in the early 
loss of muscle function in COPD, and muscle wasting can further decrease physical 
Correspondence: hyung Jung Kim
Division of Pulmonology, Department of 
Internal Medicine, gangnam severance 
hospital, Yonsei University College of 
Medicine, 211 eonju-ro, Dogok-dong, 
gangnam-gu, seoul 06273, south Korea
Tel +82 2 2019 3316
Fax +82 2 3463 3882
email khj57@yuhs.ac 
Journal name: International Journal of COPD
Article Designation: Original Research
Year: 2017
Volume: 12
Running head verso: Byun et al
Running head recto: Sarcopenia and systemic inflammation in COPD
DOI: http://dx.doi.org/10.2147/COPD.S130790
International Journal of COPD 2017:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
670
Byun et al
activity, exercise tolerance, and quality of life. Previous 
studies have reported that muscle wasting is closely associ-
ated with higher rates of COPD exacerbation and lower 
survival rates.10,11 The BODE index (body mass index [BMI], 
obstruction of airways as measured by forced expiratory 
volume in 1 second [FEV
1
], dyspnea as measured by the 
modified Medical Research Council [mMRC] dyspnea scale, 
and exercise capacity as measured by 6-minute walk dis-
tance [6MWD]) was originally designed to predict mortality 
in COPD. It also demonstrates the prognostic significance of 
muscle mass and exercise capacity (as assessed by BMI and 
6MWD) in predicting long-term outcomes.12 This concept 
recently defined as sarcopenia a clinical syndrome comprised 
of multiple factors, including physical inactivity, malnutri-
tion, inflammation, and chronic illness.13,14 The European 
Working Group on Sarcopenia in Older People (EWGSOP) 
recommends using the presence of both low muscle mass 
and low muscle function (strength or performance) for the 
diagnosis of sarcopenia.13
Initially, sarcopenia used to describe age-related loss of 
muscle mass and power. However, catabolic inflammatory 
processes often observed in chronic illnesses can enhance 
sarcopenia. As such, it has recently been recognized as a 
syndrome in various chronic conditions. Also, in the COPD 
population the prevalence of sarcopenia is reported to be 
15%, and is associated with impaired lung function and poor 
health status. No studies, however, have yet shown a direct 
association between sarcopenia and levels of inflammatory 
biomarkers in this group. We measured muscle mass and 
muscle strength in South Korean patients with stable COPD 
to determine the prevalence of sarcopenia using handgrip 
strength (HGS) and bioelectrical impedance analysis (BIA). 
In addition, we evaluated relationships between sarcopenia, 
biomarkers of systemic inflammation, disease severity, and 
other clinical features.
Materials and methods
study design and populations
Patients ($40 years old) diagnosed with COPD accord-
ing to the Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) and attending outpatient clinics between 
June 2012 and June 2014 at Gangnam Severance Hospital 
were considered eligible. Investigators explained the aim and 
protocol of the study to patients who fulfilled the inclusion 
criteria. Written informed consent and medical history were 
obtained at the visit. This was a cross-sectional study, and 
all measurements were completed at a single visit for each 
participants. Exclusion criteria were age ,40 years, presence 
of active lung disease, diagnosis of bronchial asthma, lung 
resection or transplantation, presence of severe cardiovascu-
lar disease, an episode of COPD exacerbation within the last 
month, inability to perform a 6MWD test due to severe dysp-
nea, lower-leg trauma, severe muscle weakness, and inability 
to read or understand informed consent documents. All con-
senting subjects completed a Korean version of the COPD 
Assessment Test (CAT) questionnaire (GlaxoSmithKline, 
London, UK). Subjects were evaluated using the mMRC 
dyspnea scale and postbronchodilator FEV
1
 in a pulmonary 
function test (Vmax 229; SensorMedics, Yorba Linda, CA, 
USA), 6MWD, muscle measurements, and venous blood 
sampling at a single visit. We evaluated history of exacerba-
tions in the last year, the BODE index, and disease severity 
according to a 2011 GOLD revision; the revised document 
recommends assessment of symptoms, lung function, and 
risk of exacerbation.1
This study was performed in accordance with the 
Declaration of Helsinki and South Korean good clinical 
practice guidelines. All protocols were approved by the 
institutional review board of Gangnam Severance Hospital 
(3-2011-0300).
Measurement of muscle mass and muscle 
strength
Muscle mass was quantified with BIA (Body Composition 
Analysis 1000; MediGate, Seoul, South Korea). Height (cm), 
body weight (kg), and BMI (kg/m2) were also measured. 
Fat mass index (FMI) and fat-free mass index (FFMI) were 
calculated as fat mass or fat-free mass (FFM) divided by the 
square of the patient’s height (kg/height2). Skeletal muscle 
mass index (SMMI) was calculated as skeletal muscle mass 
(SMM) divided by the square of patient’s height (kg/height2). 
Low MM was defined as having an SMMI at least two stan-
dard deviations (SDs) below normal sex-specific means in 
young persons. Data were compared with the 2008–2011 
Korean National Health and Nutrition Examination Survey 
IV and V, a nationally representative survey conducted by the 
South Korean Ministry of Health and Welfare. To determine 
muscle strength, HGS was measured using a Jamar handheld 
dynamometer (Patterson Medical, Warrenville, IL, USA), 
the reliability of which has been previously established in 
community-dwelling older adults. Subjects were seated with 
shoulders at 0° adduction and neutral rotation, elbows at 90° 
flexion, and forearms in neutral position. Three trials were 
performed with a rest period of 1 minute between trials, and 
average values were recorded. Low muscle strength was 
defined as HGS values #30 kg in men and #20 kg in women. 
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According to the recommendation of the EWGSOP,13 
sarcopenia was defined when patients had both low MM 
(assessed by decreased SMMI lower than cutoff values) and 
low muscle strength (measured by low HGS values).
Measurement of dyspnea and quality 
of life
The mMRC dyspnea scale, which uses a 0–4 scoring system, 
was used to assess shortness of breath. To assess functional 
status and exercise capacity, we used patients’ 6MWD,15 
which measures the distance that a patient can quickly walk 
along a corridor. Using these data, we measured patients’ 
BODE index. The BODE index ranges from 0 to 10 points, 
with higher scores indicating a greater risk of death in 
COPD.12 To evaluate quality of life, we used the Korean 
version of the CAT, as previously mentioned. This question-
naire consists of eight questions scored on a 0–5 scale.
Measurement of biomarkers of systemic 
inflammation
Venous blood was drawn from subjects, and circulating levels 
of biomarkers of systemic inflammation were measured using 
a high-sensitivity TNFα (hsTNFα) enzyme-linked immuno-
sorbent assay kit (Quantikine®; R&D Systems, Minneapolis, 
MN, USA) and a chemiluminescence assay to measure IL-6 
(Immulite 2000; Siemens, Munich, Germany).
statistical analyses
Statistical analyses were performed using SPSS software 
(version 23.0; IBM, Armonk, NY, USA). All data are expressed 
as means ± SD or medians with interquartile ranges. The 
Kolmogorov–Smirnov test was used to analyze normality of 
distribution. For skewed data, including serum IL-6, natural 
log values were used. Continuous variables are described as 
means ± SD, and Student’s t-test was used for comparative 
analysis. Categorical variables were analyzed using χ2 and 
t-tests with 95% confidence intervals (CIs). Pearson’s cor-
relation analysis was used to determine relationships among 
HGS, SMMI, and other clinical or inflammatory parameters. 
Multiple logistic regression analysis was performed to find 
significant determinants of sarcopenia. P,0.05 was deemed 
to indicate statistical significance.
Results
Patient characteristics
Table 1 shows 80 patients with stable COPD were included. 
Subjects were 68.4±8.9 (range 42–88) years old and 
83.8% (67) were male. Sarcopenia was prevalent in 20 (25%) 
patients. Patients with sarcopenia were significantly older, 
showed lower BMI values, and had a higher percentage of 
cardiovascular disease. FFM, FFMI, SMM, and SMMI were 
markedly decreased in sarcopenic patients with BIA. HGS 
was also lower in patients with sarcopenia. There was no 
significant difference in COPD severity between patients 
with and without sarcopenia.
Clinical outcomes associated with 
sarcopenia
Table 2 shows that compared with patients without sarcopenia, 
patients with sarcopenia had significantly more severe symp-
toms of dyspnea and higher mMRC scores, but CAT scores 
were not significantly different between the two groups. These 
patients exhibited poorer exercise tolerance, as indicated by 
Table 1 Baseline characteristics of study subjects
Variable Total 
(n=80)
With 
sarcopenia 
(n=20, 25%)
Without 
sarcopenia 
(n=60, 75%)
P-value
age (years) 68.4±8.9 73.1±8 66.8±8.7 0.006
Male (%) 67 (83.8) 17 (85) 50 (83.3) 0.585
BMI (kg/m2) 23.3±3.2 21.1±1.7 24.1±3.2 ,0.001
Comorbidities (%)
Diabetes 20 (25) 6 (30) 14 (23.3) 0.374
hypertension 38 (47.5) 12 (60) 26 (43.3) 0.181
Cardiovascular 
disease
19 (23.8) 10 (50) 9 (15) 0.003
Tuberculosis 26 (32.5) 6 (30) 20 (33.3) 0.507
Bronchiectasis/
emphysema
19 (23.8) 3 (15) 16 (26.7) 0.228
Body composition and strength
Whr 0.92±0.04 0.90±0.16 0.91±0.05 0.464
Fat mass (kg) 15.7±5.3 13.8±3.6 16.4±5.6 0.056
FMI (kg/m2) 5.8±1.9 5.1±1.4 6±2.1 0.087
Body fat (%) 24.6±5.9 24.1±5.1 24.7±6.5 0.729
FFM (kg) 47.4±6.9 42.8±4.6 49±7.4 ,0.001
FFMI (kg/m2) 17.4±1.6 15.9±1 17.9±1.5 ,0.001
sMM (kg) 25.9±4.7 22.8±3.5 27±4.6 0.001
sMMI (kg/m2) 9.5±1.2 8.5±0.8 9.8±1.1 ,0.001
hgs (kg) 30.6±9.3 25.4±6.1 32.9±9.8 0.002
Pulmonary function*
FeV1 (%) 61.2±14.3 58±13.9 62.3±13.9 0.253
FeV1/FVC (%) 51±12.9 46.1±13 52.6±12.8 0.05
gOlD stage, 2011 revised# (%) 0.624
a 24 (30) 4 (20) 20 (33.3)
B 31 (38.8) 9 (45) 22 (36.7)
C 5 (6.2) 2 (10) 3 (5) 
D 20 (25) 5 (25) 15 (25)
Notes: *Postbronchodilator; #according to 2011 gOlD revision. Data expressed 
as mean ± standard deviation or n (%).
Abbreviations: BMI, body mass index; Whr, waist:hip ratio; FMI, fat mass index; 
FFM, fat-free mass; FFMI, FFM index; sMM, skeletal muscle mass; sMMI, sMM index; 
hgs, handgrip strength; FeV1, forced expiratory volume in 1 second; FVC, forced 
vital capacity; gOlD, global Initiative for Chronic Obstructive lung Disease.
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the shorter 6MWD values. The median score in the BODE 
index was also significantly higher in patients with sarcope-
nia. There was no significant difference in the frequency 
of acute exacerbation of COPD between the two groups. 
Among inflammatory biomarkers, hsTNFα (P=0.013) and 
IL-6 (P=0.044) levels were significantly higher in patients 
with sarcopenia than patients without sarcopenia.
Correlations among hgs, sMM, and 
inflammatory biomarkers
As shown in Table 3, HGS showed positive correlations 
with FFMI, SMMI, and 6MWD and significant negative 
correlations with age, FMI, mMRC score, CAT scores, 
IL-6, and hsTNFα; SMMI positively correlated with BMI, 
HGS, FFMI, and FMI, and negatively correlated with BODE 
index, IL-6, and hsTNFα.
Figure 1 shows HGS (r=-0.35, P=0.002) and SMMI 
(r=0.246, P=0.044) levels were very closely associated with 
hsTNFα as a systemic inflammatory parameter. In addition, 
values for the BODE index tended to correlate with HGS 
and SMMI. However, FEV
1
16 did not correlate with HGS or 
SMMI in this study.
Factors associated with sarcopenia in 
patients with COPD
As shown in Table 4, cardiovascular disease, a common 
comorbidity in patients with COPD, was associated with the 
presence of sarcopenia. GOLD classification (revised in 2011) 
was not associated with sarcopenia. As a systemic inflamma-
tory biomarker, hsTNFα levels showed significant negative 
correlations with the presence of sarcopenia in our analysis. 
In multivariate analysis, significant determinants for the 
presence of sarcopenia in patients with stable COPD were 
old age (odds ratio [OR] 1.19, 95% CI 1.03–1.36), low BMI 
(OR 0.52, 95% CI 0.35–0.78), presence of previous cardio-
vascular disease (OR 4.66, 95% CI 1.01–18.31), and higher 
hsTNFα levels (OR 1.99, 95% CI 1.04–3.81).
Discussion
To summarize, the prevalence of sarcopenia in South Korean 
patients with stable COPD was 25%, which was consis-
tent with previous studies reporting prevalence rates of 
20%–40%.17–19 Patients with sarcopenia tended to be older, 
have a higher percentage of cardiovascular comorbidity, more 
severe mMRC dyspnea scores, higher BODE index scores, 
and lower exercise tolerance in the 6MWD than those without 
sarcopenia. Sarcopenia in male and female patients was 25.4% 
(17 of 67) and 23.1% (three of 13). There was no difference 
in sex. The proportion of male sex among COPD patients was 
far higher in our study. However, it was not different from 
other South Korean COPD data. According to the representa-
tive South Korean COPD cohort data of nearly 1,000 COPD 
patients, 91.2% were male, higher than our data.20
MM measured by SMMI correlated with BMI and body-
composition parameters, whereas muscle strength assessed 
by HGS significantly correlated with mMRC dyspnea scale, 
Table 2 Clinical outcomes according to presence or absence of 
sarcopenia
Variable With 
sarcopenia 
(n=20, 25%)
Without 
sarcopenia 
(n=60, 75%)
P-value
mMrC score 0.95±0.86 0.62±0.71 0.044
0–1 15 (75%) 51 (85%) 0.059
2–4 5 (25%) 9 (15%)
CaT score 15 (7–22) 14 (8.75–21.25) 0.678
,10 6 (30) 26 (43.3) 0.216
$10 14 (70) 34 (56.7)
BODe index 3 (0–6) 1 (0–4) 0.001
6MWD (m) 350.8±78 389.3±66.9 0.042
acute exacerbations 
$1/year (n)
9 (45) 22 (36.7) 0.343
Inflammatory biomarkers
Il-6* 1.36±0.81 0.64±0.69 0.044
hsTnFα* 0.72±1.01 -0.03±1.16 0.013
Notes: *log-transformed value. all data expressed as mean ± sD or n (%) except 
for CaT score, BODe index, and number of acute exacerbation in the previous year 
(median with inter-quartile ranges).
Abbreviations: mMRC, modified Medical Research Council; CAT, COPD Asses­
sment Test; 6MWD, 6-minute walk distance; hsTnFα, high-sensitivity TnFα; 
BODE, body (mass index), (airflow) obstruction, dyspnea, exercise (capacity); SD, 
standard deviation.
Table 3 Correlations among HGS, SMMI, and inflammatory 
biomarkers
Variable HGS SMMI
Coefficient P-value Coefficient P-value
age -0.415 ,0.001 -0.074 0.527
BMI 0.001 0.998 0.852 ,0.001
hgs 1 – 0.427 ,0.001
FFMI 0.346 0.002 0.99 ,0.001
FMI -0.325 0.004 0.275 0.017
sMMI 0.427 ,0.001 1 –
FeV1* -0.103 0.367 0.018 0.88
FeV1/FVC* -0.13 0.367 0.079 0.498
mMrC score -0.346 0.002 -0.062 0.595
6MWD 0.44 ,0.001 0.015 0.899
BODe index -0.216 0.045 -0.257 0.026
CaT score -0.236 0.048 -0.132 0.275
Il-6# -0.273 0.018 -0.227 0.048
hsTnFα# -0.35 0.002 -0.246 0.044
Notes: *Postbronchodilator; #log-transformed value.
Abbreviations: BMI, body mass index; hgs, handgrip strength; FFMI, fat-free mass 
index; FMI, fat mass index; sMMI, skeletal muscle mass index; FeV1, forced expiratory 
volume in 1 second; FVC, forced vital capacity; mMRC, modified Medical Research 
Council; 6MWD, 6-minute walk distance; CaT, COPD assessment Test; hsTnFα, 
high-sensitivity TnFα; BODE, body (mass index), (airflow) obstruction, dyspnea, 
exercise (capacity).
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CAT score, and 6MWD as COPD clinical parameters. Low 
HGS and SMMI showed positive correlations with the BODE 
index. These results suggest sarcopenia is closely correlated 
with the BODE index, predicting higher risk of mortality. 
Consistent with our findings, Swallow et al reported that 
muscle strength is important in patient prognosis.21 A recent 
study of patients with stable COPD using prospective multi-
center data also found that HGS correlated significantly with 
mortality.22 Therefore, HGS might provide critical prognostic 
information for patients with COPD.
In addition, the presence of sarcopenia was highly associ-
ated with levels of systemic inflammation. The mechanisms 
by which patients with COPD develop systemic inflammation 
are currently unknown. The presence of systemic inflam-
mation, however, is closely associated with complications 
that affect prognosis, such as weight loss,23,24 cachexia,25,26 
and cardiovascular disease.27,28 In a review of inflammatory 
markers in patients with COPD, CRP, fibrinogen, leukocytes, 
TNFα, IL-6, and IL-8 levels were significantly elevated 
in patients with COPD compared with healthy controls.8 
In this study, we assessed correlations of sarcopenia with 
the systemic inflammatory biomarkers IL-6 and hsTNFα. 
Muscle strength assessed by HGS and MM measured by 
SMMI showed significant correlations with levels of IL-6 
and hsTNFα. In multivariate analysis, higher hsTNFα was 
a significant determinant for the presence of sarcopenia. 
The strength of this study was that most of patients in our 
study had milder COPD severity (GOLD A/B, 68.8%) and 
all patients had stable status, not exacerbated, and signifi-
cant correlations of HGS and SMMI with levels of systemic 
inflammatory biomarkers is a noteworthy result.
In the elderly and patients with COPD, physical inactivity 
is a key factor in the development of sarcopenia and a predic-
tor of mortality and disability.29 The causes and prevalence 
of systemic inflammation and the mechanisms by which it 
leads to muscle wasting in COPD patients are uncertain. 
Previous studies have suggested that severe muscle wast-
ing can lead to cachexia during systemic inflammation.24,30 
We found that various factors were associated with sarcope-
nia, including age, BMI, and systemic inflammation. COPD 
severity, however, was not associated with the presence or 
absence of sarcopenia in this study, and the frequency of 
acute exacerbations of COPD was not different between the 
two groups. Considering the clinical complexity of COPD, 
however, we propose that multiple biomarkers are required 
Figure 1 Correlation of handgrip strength and skeletal muscle mass index with high-sensitivity TnFα.
Abbreviation: TnFα, Tumor necrosis factor alpha.
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Table 4 Factors associated with sarcopenia
Variable Sarcopenia
Univariate analysis Multivariate analysis
OR (95% CI) P-value OR (95% CI) P-value
age
Years 1.11 (1.03–1.22) 0.009 1.19 (1.03–1.36) 0.017
sex
Male vs female 1.13 (0.28–4.6) 0.861 – –
BMI
kg/m2 0.63 (0.48–0.82) 0.001 0.52 (0.35–0.78) 0.001
Diabetes
Presence 1.41 (0.38–3.02) 0.552 – –
Cardiovascular disease
Presence 5.66 (1.8–12.65) 0.003 4.66 (1.01–18.31) 0.048
gOlD stage
a–B 1 – –
C–D 1.26 (0.43–3.67) 0.676 – –
hsTnFα* 1.81 (1.1–2.99) 0.019 1.99 (1.04–3.81) 0.038
Notes: *log-transformed value. Multivariate logistic analysis was performed after 
adjusting for age, sex, BMI, and diabetes.
Abbreviations: OR, odds ratio; CI, confidence interval; BMI, body mass index; GOLD, 
global Initiative for Chronic Obstructive lung Disease; hsTnFα, high-sensitivity TnFα.
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to characterize pathogenic factors and clinical outcomes in 
this disease.31
There are several limitations to our study. We utilized a 
cross-sectional design, the study population was small, and 
recruitment was limited to outpatient clinics at a single tertiary 
hospital. Sample composition in terms of disease severity 
according to GOLD stage and FEV
1
 was not well balanced.
Conclusion
Nearly a quarter of South Korean patients with stable COPD 
have sarcopenia, and sarcopenic patients presented with 
more severe dyspnea, showed lower exercise tolerance, and 
predicted poor prognosis. In addition, sarcopenia was highly 
associated with levels of systemic inflammation. The pres-
ence of systemic inflammation was a main determinant of 
sarcopenia in a stable COPD population.
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